Regen BioPharma Acquires Issued Patent and Preclinical Data Package for Targeting Cancer Stem Cell

The intellectual property covers specific therapeutic agents that gene silence CTCFL. CTCFL, otherwise known as Brother of the Regulator of Imprinted Sites is a gene that is critical for cancer stem cells to survive, in part by inducing expression of telomerase, a protein that creates cellular immortality .

http://ift.tt/1wVZwPp